SOURCE: Golden Valley Development, Inc.

July 02, 2015 09:00 ET

Golden Valley Development, Inc. Announces XytoTest Training Program and Campaigns to Prevent Cervical Cancer in Mexico and Colombia

FORT LAUDERDALE, FL--(Marketwired - Jul 2, 2015) - Golden Valley Development, Inc. (OTC PINK: GVDI) (the "Company"), a developer and marketer of patented and patentable technologies, is pleased to announce the roll-out of their training program with their strategic partner Mel-Mont Medical, LLC, ("Mel-Mont") to instruct and prepare the necessary personnel to execute a screening campaign, using XytoTest as a Cervical Cancer detection device in Mexico and Colombia.

XytoTest™ is a self-sampling kit of cervical specimens for the analysis of DNA for the 14 high-risk strains of HPV (Human Papilloma Virus). The medical device is comprised of a hollow sheath made of special resin that meets US FDA 21 CFR 181.32 requirements. The device is user-friendly and is less than 8 millimeters in diameter. There is a cell collector of USP medical grade IV elastomer fully tested to guarantee no skin or mucous membrane irritation in accordance to ISO 10993-5 and ISO 10993-10.

"Furthering our strategic alliance with Mel-Mont, Golden Valley has developed a comprehensive training program and campaigns in two very important developing nations, Mexico and Colombia," stated Kevin Sorrels, CEO of GVDI.

Worldwide, cervical cancer is the third most common cancer in women, and the first or second most common in developing countries. Cervical cancer is a slow-growing cancer that develops in the tissues of the uterine cervix. It does not typically have any symptoms and is almost always caused by human papillomavirus (HPV) infection. Effective screening and treatments continue to decrease the incidence of cases and deaths from cervical cancer. However, women in developing countries account for the majority of cases and deaths related to this type of cancer. Over half a million cases are detected every year. According to the World Health Organization (WHO), Cervical cancer is one of the world's deadliest forms of cancer for women, responsible for more than 270 000 deaths annually, 85% of which occur in developing countries.

"The true tragedy of this, is that cervical cancer is the most easily preventable . With early detection screening widely available, and with newer self-detection devices such as XytoTest™, no woman anywhere in the world today, should have to die from cervical cancer," stated Kevin Sorrels, CEO of GVDI.

Rates of cervical cancer in Mexico and Latin America are three times higher than in the United States due to less screening. Cervical cancer remains in Colombia the first cause of cancer mortality and the second cause of cancer incidence among women, despite the existence of screening programs during the last 3 decades. Bucaramanga, Manizales and Cali reported rates around 20 per 100,000 and Pasto 27 per 100,000. The Cali cancer registry has reported a progressive decrease in the age standardized incidence and mortality rates of cervical cancer over the past 40 years. Reasons for the decline in incidence and mortality of cervical cancer may include: improvement in socio-economic conditions, decrease in parity rates and some effect of screening programs.

"Golden Valley has thus far proven instrumental in their efforts to enhance awareness for our life-saving product. The training programs being developed jointly by us and Golden Valley, will no doubt be of huge significance, with potential for deployment in other nations where the problem persists as well," stated Liliana Montes, Mel-Mont CEO.

About Golden Valley Development, Inc Golden Valley Development, Inc. ("GVDI" or "Company") is a holding company and developer and marketer of patented and patentable technologies. As a holding company GVDI is focused in technology and financial services, engaging in several business activities, the most significant being as a technology provider to third party logistic providers and as a financial service company for small-to-medium sized businesses (SMEs) worldwide.

About Mel-Mont Medical LLC Mel-Mont Medical (MMM) researches, develops and markets comprehensive healthcare programs for the vulnerable and female population using proprietary medical devices. Founded in 2014, Mel-Mont Medical develops educational and self- sampling campaigns to reduce the spread of HPV infections. Also it provides information and education about Human Papilloma Virus (HPV) as a precursor of cervical cancer within the female population sexually active. Our health programs are directed to the vulnerable, female population located in rural areas of developing countries around the globe, where traditional health care systems are difficult and complex to implement. The company operates in the USA and emerging countries including Latin and South America with a focus in Colombia where the company has offices and Mexico. www.xytotest.com.

For additional information contact Investor Relations at: info@goldenvalleydev.com

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's OTC Markets disclosures and filings (www.otcmarkets.com). The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.

Contact Information